

Monthly commentary / 30.06.2020 Vontobel Asset Management

# **Vontobel Fund - Global Equity Income**

Approved for institutional investors in: AT, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, PT, SE, SG (Professional Investors only)

# Market developments

Global equity markets continued their recovery in June as ongoing stimulus measures further fuelled returns. The MSCI Asia-Pacific ex Japan outperformed with an 8.19% return for the month with the broader MSCI Emerging Markets also up strongly as China stocks reached new 2020 highs. Shares shook off concerns of a renewal of tensions with the US as economic indicators improved. European equities strengthened slightly from May, as unlocking measures across the continent prompted hopes of a summer season economic boost. Having led the way in previous months, the US lagged as a spike in COVID-19 infections in southern states delayed re-opening in Florida and Texas, while investors also worried that the US response to China's imposition of a new security law in Hong Kong could provoke retaliation.

#### Portfolio review

We did not make any major changes to the portfolio this month.

# Performance analysis

The Real Estate and Utilities sectors were positive contributors to relative performance over the month. The Health Care and Consumer Discretionary sectors detracted from relative performance. On a country basis, Hong Kong and Japan contributed to relative performance, while the United States and Spain detracted from performance.

**TOP3 Contributors:** 

# SAP SE

From a fundamental standpoint, there is nothing company-specific to report. SAP is a German based global Enterprise Resource Planning (ERP) software company. Within large organizations around the world SAP has a near monopoly position. ERP runs core operations and hence is difficult and expensive to replace which leads to very high renewal rates. As the industry moves to a cloud and software-as-a-service (SaaS) model revenues will become even more predictable. The company reported quarterly results where they showed strong indications that they are following through with the promise that the previous heavy investment in cloud and SaaS will start to trend down. Hence margins and cash flow are improving. Additionally dilution from stock options is declining as well.

# LINK REAL ESTATE INVESTMENT

Link REIT is the largest public landlord in Hong Kong with mostly retail properties (community and neighborhood shopping centers) as well as car parks. The company also has expanded into China by way of two malls and one office building. At its inception, Link REIT purchased local retail centers in Hong Kong from the government at bargain prices. Link REIT transformed these properties from a collection of poorly run, unsophisticated shops into a modernized portfolio of local retail centers at the doorsteps of 40% of Hong Kong's population. Link has continued its asset enhancement strategy to drive higher rents while it has also embarked on an asset recycling program, selling some properties and using the proceeds to repurchase shares, buy back debt and invest in other retail properties in tier one cities in China as well as properties in other countries.

# HONG KONG EXCHANGES & CLEAR

From a fundamental standpoint, there is nothing company-specific to report. Hong Kong Exchanges & Clearing Limited (HKEx) owns and operates the only stock exchange and a futures exchange in Hong Kong, as well as their related clearing houses. Over market cycles, the company should grow faster than the market index due to market expansion, product innovation and operating leverage. HKEx provides the trading platforms for a range of cash and derivatives products and the facilities for processing trades. The company operates its business through five segments: Cash, Equity & Financial Derivatives, Commodities,

Clearing and Platform & Infrastructure.

TOP3 Detractors:

#### CME GROUP INC COM STK

CME Group underperformed because of concerns that trading volumes of interest rates futures (30%+ of their revenues) may be depressed over the short to medium term. This is due to the Fed's policy of keeping short-term interest rates near zero for an extended period of time. CME Group, the world's leading derivatives exchange group, facilitates trading across a full spectrum of derivative instruments — from equity indices to agriculture and from energy to interest rates. As a vertically-integrated futures exchange and clearing house, CME is a near-monopoly in the trading and clearing of the instruments offered on its platform. As a result, CME enjoys EBITDA margins of more than 70%. The company is also very cash flow-generative, with free cash flow conversion of more than 90%. The management is shareholder-focused and has consistently returned excess free cash flow to shareholders through share buybacks and dividends. In addition, longer term, CME should benefit from the regulatory push towards clearing more derivative transactions through central clearing houses.

# MEDTRONIC PLC COMMON STOCK STOCK

MDT's June underperformance likely reflected concerns over a second wave of COVID19. We view a potential second wave impact as more limited given more regional impacts, and continue to see MDT's business mix as defensible longer-term given the medically necessary nature of its portfolio. Medtronic is a global medical device manufacturer that has leadership positions in the pacemaker, defibrillator, orthopedic, diabetes management and other medical markets. Its business is categorized into three main groups: Cardiac and Vascular, Restorative Therapies, and Diabetes. Medtronic is well positioned to grow within the medical device industry, because demand for its mainstay acute and critical care products is not easily crimped by recession, health care reform or cost-cutting pressures.

# JOHNSON & JOHNSON COM USD1

There was no material news in June, and JNJ's underperformance likely reflected a shift out of more defensive names after strong relative performance early in the year. Johnson & Johnson (JNJ) is a diversified healthcare conglomerate with a strong presence in pharma, medical devices, and consumer health care products. In our view, the company offers a steady and dependable growth profile with diversification and a strong balance sheet adding to the company's defensiveness. Growth is currently being led by the pharma business, where JNJ is outperforming peers given strong franchises in immunology and oncology. Medical devices and consumer are steady growth businesses, and the company is taking measures to improve performance. We believe valuation is attractive given the durable and defensive profile of the businesses.

# Outlook

Earnings estimates have been beaten down for 2020, while 2021 earnings should still be below 2019 levels. The market rebound might indicate that either investors are looking through to 2022, or more likely are responding to short-term news around COVID-19 and stimulus measures. In the case of a severe second wave, the market recovery could prove fleeting. In that case, we believe high quality stocks that have secular growth behind them should do well. And active managers can use volatility as an opportunity to take advantage of the swings in the market.

### Performance (in %)

Net returns			Rolling 12-month net returns			
USD	Fund	Index	Start date	End date	Fund	Index
MTD	0.9	3.2	01.07.2019	30.06.2020	-6.6	2.1
YTD	-11.0	-6.3	01.07.2018	28.06.2019	6.6	5.7
2019	18.9	26.6	01.07.2017	29.06.2018	-0.1	10.7
3 years p.a.	-0.2	6.1	01.07.2016	30.06.2017	n/a	n/a
5 years p.a.	n/a	n/a	01.07.2015	30.06.2016	n/a	n/a
10 years p.a.	n/a	n/a	Index: MSCI All Country			
Since launch	4.3	8.6				
p.a.						
Launch Date		13.07.2007	Share class: I ISIN: LU0278093322			

Past performance is not a reliable indicator of current or future performance. Performance data does not take into account any commissions and costs charged when shares of the fund are issued and redeemed, if applicable. The return of the fund may go down as well as up due to changes in the rates of exchange between currencies.

#### **Disclaimer**

This marketing document was produced for institutional clients, for distribution in AT, CH, DE, ES, FI, FR, GB, IT, LI, LU, NL, NO, PT, SE, SG (Professional Investors only).

This document is for information purposes only and does not constitute an offer, solicitation or recommendation to buy or sell shares of the fund/fund units or any investment instruments, to effect any transactions or to conclude any legal act of any kind whatsoever. Subscriptions of shares of the fund should in any event be made solely on the basis of the fund's current sales prospectus (the "Sales Prospectus"), the Key Investor Information Document ("KIID"), its articles of incorporation and the most recent annual and semi-annual report of the fund and after seeking the advice of an independent finance, legal, accounting and tax specialist. This document is directed only at recipients who are institutional clients such as eligible counterparties or professional clients as defined by the Markets in Financial Instruments Directive 2014/65/EC ("MiFID") or similar regulations in other jurisdictions.

In particular, we wish to draw your attention to the following risks: Investments in derivatives are often exposed to the risks associated with the underlying markets or financial instruments, as well as issuer risks. Derivatives tend to carry more risk than direct investments. Investment universe may involve investments in countries where the local stock exchanges may not yet qualify as recognized stock exchanges.

# Past performance is not a reliable indicator of current or future performance.

Performance data does not take into account any commissions and costs charged when shares of the fund are issued and redeemed, if applicable. The return of the fund may go down as well as up due to changes in rates of exchange between currencies. The value of the money invested in the fund can increase or decrease and there is no guarantee that all or part of your invested capital can be redeemed.

Interested parties may obtain the above-mentioned documents free of charge from the authorized distribution agencies and from the offices of the fund at 11-13 Boulevard de la Foire, L-1528 Luxembourg, the paying agent in Austria Erste Bank der oesterreichischen Sparkassen AG, Graben 21, A-1010 Vienna, the representative in Switzerland: Vontobel Fonds Services AG, Gotthardstrasse 43, 8022 Zurich, the paying agent in Switzerland: Bank Vontobel AG, Gotthardstrasse 43, 8022 Zurich, the paying agent in Germany: B. Metzler seel. Sohn & Co. KGaA, Grosse Gallusstrasse 18, 60311 Frankfurt/Main, the paying agent in Liechtenstein: Liechtensteinische Landesbank AG, Städtle 44, FL-9490 Vaduz. Refer for more information on the fund to the latest prospectus, annual and semi-annual reports as well as the key investor information documents ("KIID"). These documents may also be downloaded from our website at vontobel.com/am.In Spain, funds authorized for distribution are recorded in the register of foreign collective investment companies maintained by the Spanish CNMV (under number 280). The KIID can be obtained in Spanish from Vontobel Asset Management S.A., Spain Branch, Paseo de la Castellana, 95, Planta 18, E-28046 Madrid or electronically from atencionalcliente@vontobel.es. The KIID is available in Finnish. The KIID is available in French. The fund is authorized to the commercialization in France since 30-DEC-16. Refer for more information on the funds to the Document d'Information Clé pour l'Investisseur (DICI). The funds authorized for distribution in the United Kingdom can be viewed in the FCA register under the Scheme Reference Number 466625. This information was approved by Vontobel Asset Management SA, London Branch, which has its registered office at Third Floor, 22 Sackville Street, London W1S 3DN and is authorized

by the Commission de Surveillance du Secteur Financier (CSSF) and subject to limited regulation by the Financial Conduct Authority (FCA). Details about the extent of regulation by the FCA are available from Vontobel Asset Management SA, London Branch, on request. The KIID can be obtained in English from Vontobel Asset Management SA, London Branch, Third Floor, 22 Sackville Street, London W1S 3DN or downloaded from our website vontobel.com/am. Refer for more information regarding subscriptions in Italy to the Modulo di Sottoscrizione. For any further information: Vontobel Asset Management S.A., Milan Branch, Piazza degli Affari 3, 20123 Milano, telefono: 0263673444, e-mail clientrelation@vontobel.it. The Fund and its subfunds are included in the register of Netherland's Authority for the Financial Markets as mentioned in article 1:107 of the Financial Markets Supervision Act ("Wet op het financiële toezicht"). The KIID is available in Norwegian. Please note that certain subfunds are exclusively available to qualified investors in Andorra or Portugal. The KIID is available in Swedish. The fund and its subfunds are not available to retail investors in Singapore. Selected subfunds of the fund are currently recognized as restricted schemes by the Monetary Authority of Singapore. These subfunds may only be offered to certain prescribed persons on certain conditions as provided in the "Securities and Futures Act", Chapter 289 of Singapore. The fund is not authorized by the Securities and Futures Commission of Hong Kong. It may only be offered to those investors qualifying as professional investors under the Securities and Futures Ordinance. The contents of this document have not been reviewed by any regulatory authority in Hong Kong. You are advised to exercise caution and if you are in any doubt about any of the contents of this document, you should obtain independent professional advice. This information was approved by Vontobel Asset Management Asia Pacific Ltd., which has its registered office at 1901 Gloucester Tower, The Landmark 15 Queen's Road Central, Hong Kong. This document is not the result of a financial analysis and therefore the "Directives on the Independence of Financial Research" of the Swiss Bankers Association are not applicable. Vontobel Asset Management AG, its affiliates and/or its board of directors, executive management and employees may have or have had interests or positions in, or traded or acted as market maker in relevant securities. Furthermore, such entities or persons may have executed transactions for clients in these instruments or may provide or have provided corporate finance or other services to relevant companies.

The MSCI data is for internal use only and may not be redistributed or used in connection with creating or offering any securities, financial products or indices. Neither MSCI nor any other third party involved in or related to compiling, computing or creating the MSCI data (the "MSCI Parties") makes any express or implied warranties or representations with respect to such data (or the results to be obtained by the use thereof), and the MSCI Parties hereby expressly disclaim all warranties of originality, accuracy, completeness, merchantability or fitness for a particular purpose with respect to such data. Without limiting any of the foregoing, in no event shall any of the MSCI Parties have any liability for any direct, indirect, special, punitive, consequential or any other damages (including lost profits) even if notified of the possibility of such damages.

Although Vontobel Asset Management AG ("Vontobel") believes that the information provided in this document is based on reliable sources, it cannot assume responsibility for the quality, correctness, timeliness or completeness of the information contained in this document. Except as permitted under applicable copyright laws, none of this information may be reproduced, adapted, uploaded to a third party, linked to, framed, performed in public, distributed or transmitted in any form by any process without the specific written consent of Vontobel. To the maximum extent permitted by law, Vontobel will not be liable in any way for any loss or damage suffered by you through use or access to this information, or Vontobel's failure to provide this information. Our liability for negligence, breach of contract or contravention of any law as a result of our failure to provide this information or any part of it, or for any problems with this information, which cannot be lawfully excluded, is limited, at our option and to the maximum extent permitted by law, to resupplying this information or any part of it to you, or to paying for the resupply of this information or any part of it to you. Neither this document nor any copy of it may be distributed in any jurisdiction where its distribution may be restricted by law. Persons who receive this document should make themselves aware of and adhere to any such restrictions. In particular, this document must not be distributed or handed over to US persons and must not be distributed in the USA.

Vontobel Asset Management AG Gotthardstrasse 43, 8022 Zürich Switzerland T +41 58 283 71 11, info@vontobel.com

vontobel.com/am